Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. - Wikidata - wikimedia - TriplyDB

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

http://www.wikidata.org/entity/Q35533503

about

Multifunctional Abl kinases in health and disease Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo.Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.The Emerging Role of ABL Kinases in Solid Tumors.Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth.Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer.Targeting BET bromodomain proteins in solid tumors Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease.A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.AR Signaling in Breast Cancer.MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model.The kinome 'at large' in cancer.An Optimized Chromatographic Strategy for Multiplexing In Parallel Reaction Monitoring Mass Spectrometry: Insights from Quantitation of Activated Kinases.Combine and conquer: challenges for targeted therapy combinations in early phase trials.Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.Kruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Targeting the Breast Cancer Kinome.Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness.Exploiting receptor tyrosine kinase co-activation for cancer therapy.Advances in mass spectrometry based strategies to study receptor tyrosine kinases.Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals.BET Bromodomain Proteins as Cancer Therapeutic Targets.Non-kinase targets of protein kinase inhibitors.

P2860

Q26771277-33C5652C-AE6D-4B27-AFAF-3CC86B6CEBBF Q33767497-A945A217-D44D-4FC8-86BF-051957D3CCFC Q36022273-F46DB6FF-35DC-4801-8234-266F41825BF2 Q36250585-25F742B4-4657-4F34-B446-F5CBF39BCC56 Q36306149-78291734-5B77-47F6-AA6A-CD842C540FC1 Q36310219-D6932502-3A5E-4E8A-A391-A3FCB55690DB Q36311216-F7B825FE-89D0-49B5-9693-31985012119F Q36347666-3C462412-16EF-4B27-881F-B4CAE102E655 Q36471425-DE88015D-A6AE-43AD-8349-BC2AEA83E473 Q36887270-337CAFBA-07BE-4B1F-AB87-A7179D66645B Q36956610-3AF0E164-67FD-41F5-82EE-50B778EEADDE Q36986274-6F174F45-FA4F-425A-8CF7-25B7F7E5E647 Q37031949-02046310-6B01-44FC-B51C-C3A0941B398A Q37096669-4CF3949A-828F-4917-87F8-C4651247786D Q37536618-8EAECE7A-3DE1-401A-A3D3-6D50707D79F9 Q37566368-AF70D0DE-47A7-4736-8398-1D4AC06FD380 Q37619860-3558280F-AB4C-4D8F-BAFA-76324B2E9705 Q37663035-697159E3-2F9A-4B51-B5AD-1584FF7C7317 Q37694673-A8F4C9EF-931E-4A5A-9CAE-2294A82E8B6F Q37696325-91ADB02B-EF57-47D8-89C0-85C81BB74085 Q37702577-D3E0C6F6-731D-4ECF-B84E-E99B60FFF110 Q37721492-F743E435-A8C9-47BE-9F8F-177A4DBE6D9E Q38548766-100D0F6F-9082-4F56-A616-06B1D2B09189 Q38551269-60E098EB-5912-4117-AB61-07D25B25FFBA Q38715428-81751466-2125-4616-A948-48634C704A6F Q38726735-EDBBB6CB-4D9E-42A6-BCB2-9E69885D0A55 Q38734451-7A3DC1CF-D588-482B-A379-9ED252E2652F Q38741165-026F8872-5E05-423C-80A7-16666A0792F6 Q38745849-0820F733-B26F-4C8C-B44D-435FC5CA1A05 Q38766891-C7EA14C4-5ABC-44D2-B13F-307627AA6A0F Q38768833-6576380C-732B-48DF-ADD9-85FD5EE9A0EB Q38812867-9C9CAC8C-D70E-4DF9-A3C5-2E5EE29268EF Q38836110-B535C1B0-C0E0-41C0-912D-C5FF3D9BD500 Q38850598-7AF12BB5-2A3B-4FD1-A6DC-90D33B1FB2FB Q38890318-AD96F5C7-C640-440D-93A3-AE717F434B32 Q38906990-63FED1F8-E0F8-4DF3-A459-B563309FA359 Q38934587-535E5026-C3EA-41AA-9ADA-B2BEA58D4735 Q38941812-5E640A6C-802C-464E-9D96-7C77E2DD79DD Q39071349-DAE1D77D-889A-4FBC-AFCC-8EB7585AA9BB Q39171961-F88D1FEF-C6A2-4F0D-973F-640A06A461A3

P2860

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

http://www.wikidata.org/entity/Q35533503

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Inhibition of Lapatinib-Induce ...... eting BET Family Bromodomains.

@ast

Inhibition of Lapatinib-Induce ...... eting BET Family Bromodomains.

@en

type

label

Inhibition of Lapatinib-Induce ...... eting BET Family Bromodomains.

@ast

Inhibition of Lapatinib-Induce ...... eting BET Family Bromodomains.

@en

prefLabel

Inhibition of Lapatinib-Induce ...... eting BET Family Bromodomains.

@ast

Inhibition of Lapatinib-Induce ...... eting BET Family Bromodomains.

@en

P1433

Q35533503-8CEC5F42-842F-49D1-8920-16860E248867

P1476

Q35533503-1B343FFF-1A49-40A7-8D29-E044E4CB704F

P2093

Q35533503-0DDD4735-FFE5-4D65-8EC7-81C4858ED0AF

Q35533503-3B5C3F33-618A-4E6C-AAEA-BC062F984019

Q35533503-4CB96F7C-C16A-46CF-AE51-A8E9FBE1DBB1

Q35533503-55E2E43E-7FDA-49CF-865F-7CD415B10893

Q35533503-6EB62A35-2075-414A-BCB1-A09462AFC896

Q35533503-6F6B2FCD-89DF-433E-A829-8278DC149663

Q35533503-80C70C64-A94D-4188-93A9-DF5E01BD6AF5

Q35533503-8EEF2A5E-9882-4D87-B919-2F4882944F98

Q35533503-9D2AE8A5-7EB2-4FDF-93F5-C8F132BAE845

Q35533503-A45BEA7B-F863-4C22-AC9C-07280F1536C7

P2860

Q35533503-03FDD18C-54D8-4FCA-B8F9-20E47A186855

Q35533503-095BEE46-20E3-4D97-B784-BF1D5F6B4B09

Q35533503-19F32D64-80F5-43ED-9D9C-8A9AAD6E5356

Q35533503-23A94C87-E334-46C4-82BA-4B066227846A

Q35533503-3B960995-F680-4838-8337-6E9BFE5A5CA2

Q35533503-453A1206-8B39-4578-808A-AB5CD331D982

Q35533503-4FFA15BD-612D-4577-9A04-5694CC4A571D

Q35533503-50A4A041-7F41-4B28-AF97-C689A89B8C4B

Q35533503-517BB279-F672-47D1-91F3-A2290977FE41

Q35533503-67694C83-0881-4901-8952-EA430791F05F

P304

Q35533503-E48F2714-DE24-4E67-B9B2-32A6902EE8F4

P31

Q35533503-7079D888-1F5B-405A-AFFE-A80D63F3E20F

P356

Q35533503-B9281002-F12A-4028-BA23-B3CF26478590

P433

Q35533503-A1B31A88-B101-4252-9D79-4EEE3B4CC7B2

P478

Q35533503-5063D90B-13A8-4807-A6B9-79ACF9AE33FE

P50

Q35533503-414E6A54-DEA2-40F2-92A5-85DAC1F792BD

P577

Q35533503-239D7EA4-92B3-4774-95C2-975AEA154F78

P698

Q35533503-FCF8F292-51F9-4526-98DF-99EC04AA3B95

P921

Q35533503-EFF2B6FE-44DD-4AC4-9E21-EA9BEC57DD65

P932

Q35533503-7538D664-C21C-464E-AF85-11F1D8991E8E

P356

J.CELREP.2015.03.037

P1433

P1476

Inhibition of Lapatinib-Induce ...... eting BET Family Bromodomains.

@en

P2093

Adriana S Beltran

http://www.w3.org/2001/XMLSchema#string

Deborah A Granger

http://www.w3.org/2001/XMLSchema#string

Gary L Johnson

http://www.w3.org/2001/XMLSchema#string

H Shelton Earp

http://www.w3.org/2001/XMLSchema#string

James S Duncan

http://www.w3.org/2001/XMLSchema#string

Jian Jin

http://www.w3.org/2001/XMLSchema#string

Joel S Parker

http://www.w3.org/2001/XMLSchema#string

Jon S Zawistowski

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Nakamura

http://www.w3.org/2001/XMLSchema#string

Kyla A L Collins

http://www.w3.org/2001/XMLSchema#string

P2860

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.

Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.

P304

390-404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELREP.2015.03.037

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25865888

http://www.w3.org/2001/XMLSchema#string

P921

P932

4408261

http://www.w3.org/2001/XMLSchema#string